XBI SPDR S&P Biotech ETF : Bullish and Bearish Analyst Opinions

Biotech M&A will continue to be strong.

Buy healthcare and biotech for AI benefits.

Growth trade rebuilding supports risk-on assets.

Speaker presents charts showing the Biotech ETFs (XBI - equal-weighted, IBB - cap-weighted) are "acting great technically" and consolidating, with the XBI/IBB ratio suggesting further relative upside for XBI. The improving technical posture, after a prolonged period of weakness, indicates building momentum and a potential breakout. LONG on biotech ETFs, with a preference for the equal-weighted XBI based on the ratio chart. A broader market sell-off negating the sector's technical strength.

Musk's strong, forward-looking confidence in Neuralink's groundbreaking medical technology suggests a bullish outlook for innovative biotech companies pushing the boundaries of human augmentation, with sentiment likely bleeding into the broader sector.

The user anticipates outperformance for the XBI biotech ETF following double M&A activity.

The author uses sarcasm to highlight the poor performance of biotech stocks within the XBI index.

You have the large pharmaceutical companies which have these patent cliffs coming off. They're going to lose exclusivity and they need to fill that pipeline... they have an exceeding amount of financial ability and capital to do that. Big Pharma is facing an existential revenue threat as blockbuster drugs lose patent protection. Armed with massive cash reserves, they will be forced to aggressively acquire small and mid-cap biotech companies—specifically in oncology, immunology, and cardiometabolic spaces—to buy innovation, driving up valuations across the entire biotech sector. LONG. A target-rich environment combined with desperate, cash-rich buyers will create significant buyout premiums for innovative biotech firms. Increased FTC antitrust scrutiny could chill mega-mergers, or high-profile clinical trial failures could reduce the pool of viable acquisition targets.

"There is a real pall over the industry... investors who say how can we possibly invest in these things if the guidance... is not held true." The discussion highlights a breakdown in trust between the FDA and biotech innovators, specifically regarding "Complete Response Letters" (rejections) and changing goalposts. Without regulatory certainty, capital allocation into speculative biotech (represented by XBI) becomes gambling rather than investing. AVOID the biotech sector until FDA leadership stabilizes or approval rates normalize. A surprise replacement of FDA leadership that restores investor confidence.

"I think really the only other two spaces that are as exciting [as crypto] would be... AI robotics and biotech." A major VC general partner explicitly identifies these two sectors as the only other "frontier tech" areas worthy of capital deployment alongside crypto. This suggests smart money flows will concentrate here, benefiting the sector ETFs. LONG on secular growth trends and VC capital allocation focus. High interest rates (if inflation spikes) disproportionately hurt long-duration growth assets like biotech and robotics.

The author was laid off from a "senior biotech admin" role and states the only job offers they can find are for roughly 25% of their previous salary. This implies a significant downturn or wage compression within the biotech industry, suggesting that companies are either struggling, cutting costs aggressively, or that high-paying roles have evaporated. The author's personal employment situation provides a negative anecdotal data point on the health of the biotech labor market, which could be a leading indicator of broader sector weakness. This is a single, personal anecdote. The author's inability to find a comparable job could be due to personal factors (e.g., niche skills, poor interviewing) rather than a systemic industry issue.

Life Biosciences (private) reached an agreement with the FDA to treat humans with Yamanaka factors to reverse aging in the eye. This is the first human application of cellular rejuvenation technology. Success here validates the entire longevity/epigenetic reprogramming sector, likely sparking a boom in related public biotech stocks. WATCH. While the specific company is private, positive Phase 1 results will lift the entire genomics/longevity sector. Clinical trials fail or show adverse effects (e.g., cancer risk associated with cellular reprogramming).

Kass argues that if value is extracted from the S&P 500 (specifically software), it must go somewhere else. AI reduces the cost of creating software, which is deflationary for the Tech sector but inflationary for sectors that rely on physical/biological reality. Capital will rotate into "Novel Sciences" (Biotech), "Building the Real World" (Construction), and "Human Connection" (Hospitality). Long Biotech / Construction / Hospitality as the counter-cyclical trade to AI software deflation. High interest rates hurting capital-intensive sectors like construction and biotech.

"If value comes out of... software in particular, it's gonna go somewhere else... My bet for the last four years has been bio and life sciences... molecular particle material, construction, and anything building in the real world, hospitality, entertainment." This is Second-Order Thinking. As the cost of intelligence (software/analysis) drops to near zero, the sectors that were previously limited by high R&D or coordination costs (Biotech, Construction, Materials) become the primary beneficiaries. The value lost by SaaS flows into "Atoms" (physical world) rather than "Bits." LONG. Rotate exposure from pure software into physical industries and novel sciences. Regulatory hurdles in bio/construction or a general recession slowing down physical economy spending.

Dr. Oz highlighted the administration's support for "curative" therapies like CRISPR for sickle cell, despite high upfront costs ($2M), because they save money long-term ($10M). The administration is explicitly shifting payment models to accommodate high-cost gene therapies. With FDA Commissioner Marty Makary (described as "brave" and pro-innovation) leading approvals, the regulatory environment for gene editing is highly favorable. LONG on regulatory tailwinds and reimbursement support. Clinical trial failures; Dr. Prasad (Biologics) potentially rolling back some initiatives (internal conflict mentioned).

The author expects a significant increase in merger and acquisition activity in the biotech sector, which would act as a bullish catalyst for valuations.

"To an extent, in our current portfolio, we have all of that [efficacy, safety, comorbidities]... We also have the best in class oral already on the market... and the senagemtide offering that is starting phase three." When asked about M&A to bolster the pipeline, the CSO pivoted to praising their internal assets (Amycretin, Tri-agonists). This signals a reluctance to pay high premiums for external biotech assets in the near term, dampening M&A speculation for smaller obesity players hoping for a Novo buyout. Avoid buying speculative small-cap obesity biotechs solely on the premise of a near-term Novo acquisition. Novo panics due to continued stock underperformance and executes a "buy vs. build" pivot.

Big Pharma engaged in $138B of M&A last year due to looming patent cliffs. The "nuclear winter" for biotech (2021-2024) is ending. Pharma giants *must* buy innovation to replace expiring revenue streams. This capital recycling, combined with a rotation out of tech, creates a favorable environment for biotech IPOs and acquisitions in 2026. LONG Biotech and Pharma (specifically Immunology/Inflammation). Regulatory crackdown on drug pricing or M&A antitrust blocking.

Altman explicitly warns: "For an obvious example, they'll be extremely capable bio models available open source that could help people create new pathogens. We need a society wide approach about how we're going to defend against this." If AI democratizes the ability to create pathogens, the value of the "shield" (rapid vaccine development, pathogen detection, and biosecurity infrastructure) skyrockets. Governments will be forced to subsidize and stockpile biodefense capabilities as a hedge against AI-accelerated bioterrorism. LONG. This is a specific, non-correlated hedge against the "dark side" of AI progress. False alarms or slow government procurement cycles.

The head of the FDA is calling for a potential policy shift toward faster drug approvals to maintain competitiveness with China, which would act as a significant tailwind for the US biotech industry if implemented.

Gottlieb cites a Wall Street Journal editorial noting FDA leader Vinay Prasad rejected Moderna's (MRNA) mRNA vaccine without a cursory review. This "arbitrary" regulatory behavior increases the cost of capital and unpredictability for the entire sector. Gottlieb notes investment in vaccines and cell/gene therapies is drying up in the US and shifting to China (where half of the global mRNA pipeline now sits). The regulatory environment in the US has become hostile to innovation, making the sector uninvestable in the medium term until leadership changes. A change in FDA administration or successful appeals by pharma companies could reverse sentiment.

The narrator states that quantum supremacy "could mean accelerated progress in areas like drug research, artificial intelligence, defense and finance." These sectors are the direct beneficiaries of quantum utility. The ability to process data in parallel (qubits) rather than sequentially (bits) unlocks capabilities in molecular modeling (Biotech), encryption (Defense), and complex market simulation (Finance) that are currently impossible. Long the downstream sectors that will leverage quantum speed to revolutionize their R&D and operational efficiency. The technology remains experimental; failure to achieve stability means these sectors cannot yet deploy these tools.

Raimondo defines economic security as "leading in artificial intelligence, leading in biotech and quantum" and states the US must "make sure that we are winning the AI race." The US government views these specific sectors not just as commercial industries but as components of "military might." This implies sustained government funding, defense contracts, and protectionist policies to ensure US hegemony over China in these fields. LONG US strategic technology sectors (AI, Quantum, Biotech) as they are effectively government-backed imperatives. High valuation multiples in tech; potential export controls limiting total addressable market (TAM) in China.

Investment capital is fleeing the vaccine research sector. Gottlieb notes that research into vaccines for Epstein-Barr Virus (EBV), MS, and cancer prevention is being pulled back. The political and regulatory environment has become hostile. It is increasingly difficult to get vaccines through the FDA due to policy changes, and even if approved, the CDC is showing reluctance to recommend them due to anti-vaccine sentiment. Gottlieb states that as a Venture Capital partner, he sees it is "very hard to get a new vaccine program funded" right now. A shift in political sentiment or a new public health crisis forcing a regulatory pivot.

Biotech is the most uncorrelated sector with the highest dispersion. 70% of unprofitable biotechs lose money, but the sector has experienced a massive drawdown (historically followed by massive recoveries). The "baby has been thrown out with the bathwater." A systematic approach filtering for "Quality" (owned by specialists) and "Value" (low Market Cap relative to R&D Spend) identifies winners in a sector where generalist capital has fled. LONG. The sector offers "lottery ticket" positive skewness after a deep cyclical bottom. High failure rate of individual clinical trials; interest rate sensitivity for unprofitable companies.